Organogenesis Holdings Inc (ORGO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $105.15M
Last updated: Nov 17, 2026 at 11:06 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 31.3% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 37.0, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about ORGO
Government Contracts
Top agency: Department of Defense at 100.0% of trailing twelve month obligations across 1 agencies
Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.
News
ORGO Valuation
Organogenesis Holdings (ORGO) trades at 12.7x forward earnings.
- Forward P/E
- 12.7x
- P/FCF
- -1618.6x
- P/B
- 0.9x
ORGO Profitability: Margins, ROIC and FCF
Organogenesis Holdings (ORGO) has a gross margin of 65.6%, an operating margin of -22.6% and a net margin of -38.5%. It posts -66.3% ROIC and a -0.0% FCF margin.
- Gross margin
- 65.6%
- Operating margin
- -22.6%
- Net margin
- -38.5%
- ROIC
- -66.3%
- ROE
- -41.7%
- FCF margin
- -0.0%
- FCF yield
- -0.1%
Organogenesis Holdings Competitors
The companies most similar to Organogenesis Holdings (ORGO) include OrganiGram Holdings, Journey Medical and Akebia Ther.
Sector: Healthcare
Companies most similar to Organogenesis HoldingsORGO Bull Case vs Bear Case
Bear case
- ORGO has a -38.5% net profit margin.
- ORGO beat EPS estimates in 37.5% of its last 8 reported quarters.
- ORGO's quarterly revenue changed -69.9% year over year.
ORGO Earnings: Beat Rate and Next Report
Organogenesis Holdings (ORGO) beat the EPS estimate in 3 of the last 8 quarters (37.5%). Its next report is expected on Feb 24, 2027.
- Beat rate
- 3 of 8 quarters (37.5%)
- Average surprise
- -100.2%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.13
ORGO Earnings Date
ORGO reports Feb 24, 2027. The date is estimated.
ORGO Earnings Call
The latest ORGO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptORGO ETF Holders
GNG tracks 8 ETFs that hold ORGO. The largest weights:
- iShares Russell 2000 ETF (IWM), 0.02% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- Dimensional U.S. Core Equity 2 ETF (DFAC), <0.01% of the fund
- Fidelity Enhanced Small Cap Core ETF (FESM), <0.01% of the fund
Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About ORGO
When does ORGO report earnings?
Organogenesis Holdings Inc (ORGO) is expected to report earnings on Feb 24, 2027.
Does ORGO pay dividends?
Organogenesis Holdings Inc (ORGO) does not currently pay a regular dividend.
What is ORGO's market cap?
Organogenesis Holdings Inc (ORGO) has a market capitalization of $105.15M with a current stock price of $0.80.
ORGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.